(PTCT) PTC Therapeutics - Ratings and Ratios
Translarna, Emflaza, Upstaza, Evrysdi, Tegsedi
PTCT EPS (Earnings per Share)
PTCT Revenue
Description: PTCT PTC Therapeutics August 03, 2025
PTC Therapeutics Inc (NASDAQ:PTCT) is a biopharmaceutical company specializing in the discovery, development, and commercialization of treatments for rare disorders. The companys product portfolio includes Translarna, Emflaza, Upstaza, Tegsedi, Waylivra, and Evrysdi, targeting conditions such as Duchenne muscular dystrophy, aromatic l-amino acid decarboxylase deficiency, and spinal muscular atrophy.
From a business perspective, PTC Therapeutics has established collaborations with major pharmaceutical companies, including F. Hoffman-La Roche Ltd. and Novartis Pharmaceuticals Corporation, to advance its pipeline products. The companys development pipeline is robust, with Sepiapterin, PTC518, and vatiquinone being key candidates targeting phenylketonuria, Huntingtons disease, and Friedreichs ataxia, respectively.
To evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, product adoption rates, and pipeline progress are crucial. Notably, the companys revenue has been driven by the sales of its marketed products, including Upstaza, which is sold under the brand name Kebilidi in the United States. Additionally, metrics such as research and development (R&D) expenses as a percentage of revenue, and the companys cash burn rate, will be essential in assessing its financial sustainability.
From a valuation perspective, PTCTs market capitalization stands at approximately $3.9 billion, with a forward price-to-earnings (P/E) ratio of 5.51, indicating a relatively low valuation compared to its peers. However, the companys return on equity (RoE) is negative, at -71.70%, suggesting that it is not generating profits. As a Trading Analyst, it is essential to closely monitor the companys progress in advancing its pipeline products, achieving regulatory approvals, and driving revenue growth to assess its potential for future profitability.
PTCT Stock Overview
| Market Cap in USD | 5,380m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2013-06-20 |
PTCT Stock Ratings
| Growth Rating | 56.7% |
| Fundamental | 79.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 46.5% |
| Analyst Rating | 4.0 of 5 |
PTCT Dividends
Currently no dividends paidPTCT Growth Ratios
| Growth Correlation 3m | 96.9% |
| Growth Correlation 12m | 63.7% |
| Growth Correlation 5y | -3.8% |
| CAGR 5y | 24.27% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.35 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.87 |
| Sharpe Ratio 12m | 0.80 |
| Alpha | 68.19 |
| Beta | 0.493 |
| Volatility | 52.14% |
| Current Volume | 1407.1k |
| Average Volume 20d | 994.3k |
| Stop Loss | 69.6 (-4.1%) |
| Signal | 1.08 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (751.7m TTM) > 0 and > 6% of Revenue (6% = 106.7m TTM) |
| FCFTA 0.27 (>2.0%) and ΔFCFTA 37.93pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 64.16% (prev 74.48%; Δ -10.32pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.27 (>3.0%) and CFO 715.5m <= Net Income 751.7m (YES >=105%, WARN >=100%) |
| Net Debt (-262.5m) to EBITDA (899.8m) ratio: -0.29 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.32 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (87.1m) change vs 12m ago 13.25% (target <= -2.0% for YES) |
| Gross Margin 99.66% (prev 77.59%; Δ 22.07pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 79.32% (prev 48.89%; Δ 30.43pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.29 (EBITDA TTM 899.8m / Interest Expense TTM 138.1m) >= 6 (WARN >= 3) |
Altman Z'' 0.89
| (A) 0.43 = (Total Current Assets 2.01b - Total Current Liabilities 866.2m) / Total Assets 2.64b |
| (B) -1.07 = Retained Earnings (Balance) -2.83b / Total Assets 2.64b |
| warn (B) unusual magnitude: -1.07 — check mapping/units |
| (C) 0.39 = EBIT TTM 868.7m / Avg Total Assets 2.24b |
| (D) -1.01 = Book Value of Equity -2.82b / Total Liabilities 2.80b |
| Total Rating: 0.89 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 79.50
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 17.13% = 5.0 |
| 3. FCF Margin 39.48% = 7.50 |
| 4. Debt/Equity -2.63 = -2.50 |
| 5. Debt/Ebitda -0.29 = 2.50 |
| 6. ROIC - WACC (= 961.8)% = 12.50 |
| 7. RoE -182.7% = -2.50 |
| 8. Rev. Trend 27.83% = 2.09 |
| 9. EPS Trend 58.26% = 2.91 |
What is the price of PTCT shares?
Over the past week, the price has changed by +6.58%, over one month by +12.02%, over three months by +41.34% and over the past year by +68.11%.
Is PTC Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PTCT is around 71.05 USD . This means that PTCT is currently overvalued and has a potential downside of -2.12%.
Is PTCT a buy, sell or hold?
- Strong Buy: 7
- Buy: 3
- Hold: 5
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the PTCT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 67.9 | -6.4% |
| Analysts Target Price | 67.9 | -6.4% |
| ValueRay Target Price | 78.4 | 7.9% |
PTCT Fundamental Data Overview November 06, 2025
P/E Trailing = 9.6057
P/E Forward = 6.006
P/S = 3.048
P/B = 1743.2734
P/EG = 0.81
Beta = 0.493
Revenue TTM = 1.78b USD
EBIT TTM = 868.7m USD
EBITDA TTM = 899.8m USD
Long Term Debt = 2.11b USD (from longTermDebt, last fiscal year)
Short Term Debt = 300.8m USD (from shortTermDebt, last quarter)
Debt = 410.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -262.5m USD (from netDebt column, last quarter)
Enterprise Value = 4.10b USD (5.38b + Debt 410.1m - CCE 1.69b)
Interest Coverage Ratio = 6.29 (Ebit TTM 868.7m / Interest Expense TTM 138.1m)
FCF Yield = 17.13% (FCF TTM 702.5m / Enterprise Value 4.10b)
FCF Margin = 39.48% (FCF TTM 702.5m / Revenue TTM 1.78b)
Net Margin = 42.25% (Net Income TTM 751.7m / Revenue TTM 1.78b)
Gross Margin = 99.66% ((Revenue TTM 1.78b - Cost of Revenue TTM 6.01m) / Revenue TTM)
Gross Margin QoQ = 92.52% (prev 91.35%)
Tobins Q-Ratio = 1.55 (Enterprise Value 4.10b / Total Assets 2.64b)
Interest Expense / Debt = 7.95% (Interest Expense 32.6m / Debt 410.1m)
Taxrate = 168.9% (out of range, set to none) (-39.0m / -23.1m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 2.32 (Total Current Assets 2.01b / Total Current Liabilities 866.2m)
Debt / Equity = -2.63 (negative equity) (Debt 410.1m / totalStockholderEquity, last quarter -155.8m)
Debt / EBITDA = -0.29 (Net Debt -262.5m / EBITDA 899.8m)
Debt / FCF = -0.37 (Net Debt -262.5m / FCF TTM 702.5m)
Total Stockholder Equity = -411.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 28.43% (Net Income 751.7m / Total Assets 2.64b)
RoE = -182.7% (negative equity) (Net Income TTM 751.7m / Total Stockholder Equity -411.5m)
RoCE = 51.16% (EBIT 868.7m / Capital Employed (Equity -411.5m + L.T.Debt 2.11b))
RoIC = 969.1% (EBIT 868.7m / (Assets 2.64b - Curr.Liab 866.2m - Cash 1.69b))
WACC = 7.28% (E(5.38b)/V(5.79b) * Re(7.83%) + (debt cost/tax rate unavailable))
Discount Rate = 7.83% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 7.41%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈702.5m ; Y1≈461.2m ; Y5≈210.9m
Fair Price DCF = 52.19 (DCF Value 4.15b / Shares Outstanding 79.4m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 58.26 | EPS CAGR: 54.38% | SUE: 0.31 | # QB: 0
Revenue Correlation: 27.83 | Revenue CAGR: 8.78% | SUE: 0.12 | # QB: 0
Additional Sources for PTCT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle